Real-World Treatment Patterns and Outcomes of Zanubrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia (CLL/SLL).

ABSTRACT: Zanubrutinib is a next-generation selective Bruton's tyrosine kinase inhibitor (BTKi) with superior efficacy and lower cardiotoxicity rates seen in clinical trials over first-generation ibrutinib in CLL/SLL patients. We present real-world treatment patterns based on a practice change from ibrutinib to zanubrutinib in CLL/SLL patients in an integrated community oncology practice. We retrospectively analyzed adult patients who filled at least 3 months of zanubrutinib at Kaiser Permanente Northern California. Treatment patterns, adverse events (AE), and mortality were reported. Two hundred eighty-one patients received zanubrutinib; 190 patients switched from ibrutinib. Similar AE rates were seen with both BTKis, with a lower proportion of patients with treatment-limiting AEs and lower cardiac

SUBMITTER: Krackeler ML 

PROVIDER: S-EPMC12522175 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature